Renal Division, Brigham & Women's Hospital, Boston, MA; Division of Nephrology and Hypertension, Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.
Renal Division, Brigham & Women's Hospital, Boston, MA.
Am J Kidney Dis. 2018 Mar;71(3):362-370. doi: 10.1053/j.ajkd.2017.08.017. Epub 2017 Nov 11.
Serum uric acid concentrations increase in chronic kidney disease (CKD) and may lead to tubular injury, endothelial dysfunction, oxidative stress, and intrarenal inflammation. Whether uric acid concentrations are associated with kidney failure and death in CKD is unknown.
Prospective observational cohort study.
SETTINGS & PARTICIPANTS: 3,885 individuals with CKD stages 2 to 4 enrolled in the Chronic Renal Insufficiency Cohort (CRIC) between June 2003 and September 2008 and followed up through March 2013.
Baseline uric acid concentrations.
Kidney failure (initiation of dialysis therapy or transplantation) and all-cause mortality.
During a median follow-up of 7.9 years, 885 participants progressed to kidney failure and 789 participants died. After adjustment for demographic, cardiovascular, and kidney-specific covariates, higher uric acid concentrations were independently associated with risk for kidney failure in participants with estimated glomerular filtration rates (eGFRs) ≥ 45mL/min/1.73m (adjusted HR per 1-standard deviation greater baseline uric acid, 1.40; 95% CI, 1.12-1.75), but not in those with eGFRs<30mL/min/1.73m. There was a nominally higher HR in participants with eGFRs of 30 to 44mL/min/1.73m (adjusted HR, 1.13; 95% CI, 0.99-1.29), but this did not reach statistical significance. The relationship between uric acid concentration and all-cause mortality was J-shaped (P=0.007).
Potential residual confounding through unavailable confounders; lack of follow-up measurements to adjust for changes in uric acid concentrations over time.
Uric acid concentration is an independent risk factor for kidney failure in earlier stages of CKD and has a J-shaped relationship with all-cause mortality in CKD. Adequately powered randomized placebo-controlled trials in CKD are needed to test whether urate lowering may prove to be an effective approach to prevent complications and progression of CKD.
血清尿酸浓度在慢性肾脏病(CKD)中升高,可能导致肾小管损伤、内皮功能障碍、氧化应激和肾内炎症。尿酸浓度是否与 CKD 中的肾衰竭和死亡相关尚不清楚。
前瞻性观察队列研究。
2003 年 6 月至 2008 年 9 月期间纳入慢性肾功能不全队列(CRIC)的 3885 名 CKD 2 至 4 期患者,并随访至 2013 年 3 月。
基线尿酸浓度。
肾衰竭(开始透析治疗或移植)和全因死亡率。
在中位随访 7.9 年期间,885 名参与者进展为肾衰竭,789 名参与者死亡。在调整人口统计学、心血管和肾脏特异性协变量后,较高的尿酸浓度与估计肾小球滤过率(eGFR)≥45mL/min/1.73m2 的参与者的肾衰竭风险独立相关(每 1 个标准差尿酸基线增加的调整后的 HR 为 1.40;95%CI,1.12-1.75),但在 eGFR<30mL/min/1.73m2 的参与者中则不然。eGFR 为 30 至 44mL/min/1.73m2 的参与者的 HR 略高(调整后的 HR,1.13;95%CI,0.99-1.29),但无统计学意义。尿酸浓度与全因死亡率之间呈 J 形关系(P=0.007)。
由于无法获得混杂因素,可能存在潜在的残余混杂;缺乏随时间变化的尿酸浓度的随访测量来调整。
尿酸浓度是 CKD 早期阶段肾衰竭的独立危险因素,与 CKD 中的全因死亡率呈 J 形关系。需要进行足够规模的随机安慰剂对照试验来检验降低尿酸是否可能成为预防 CKD 并发症和进展的有效方法。